Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Faviprevir in COVID-19 Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04351295
Recruitment Status : Not yet recruiting
First Posted : April 17, 2020
Last Update Posted : April 17, 2020
Sponsor:
Information provided by (Responsible Party):
Sherief Abd-Elsalam, Tanta University

Brief Summary:
Faviprevir in COVID-19 treatment

Condition or disease Intervention/treatment Phase
COVID Drug: Favipiravir Drug: Placebos Phase 2 Phase 3

Detailed Description:
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment
Estimated Study Start Date : April 17, 2020
Estimated Primary Completion Date : December 1, 2030
Estimated Study Completion Date : December 1, 2030

Arm Intervention/treatment
Experimental: Faviprevir
Faviprevir
Drug: Favipiravir
Favipiravir
Other Name: Faviprevir

Placebo Comparator: Placebo
Placebo
Drug: Placebos
Placebo oral tablet
Other Name: Placebo




Primary Outcome Measures :
  1. Number of patients with viral cure [ Time Frame: 6 months ]
    The total number of patients with viral cure



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with covid 19

Exclusion Criteria:

  • Allergy or contraindications to faviprevir

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04351295


Contacts
Layout table for location contacts
Contact: Sherief Abd-Elsalam, ass. prof. 00201147773440 sheriefabdelsalam@yahoo.com

Locations
Layout table for location information
Egypt
Tanta University
Tanta, Egypt, 35111
Sponsors and Collaborators
Tanta University
Investigators
Layout table for investigator information
Principal Investigator: sherief Abd-Elsalam, Ass. Prof. Tanta University - Faculty of Medicine
Layout table for additonal information
Responsible Party: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University
ClinicalTrials.gov Identifier: NCT04351295    
Other Study ID Numbers: faviprevir covid
First Posted: April 17, 2020    Key Record Dates
Last Update Posted: April 17, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No